Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS).

Sdz-adl (gp2017; sandoz gmb h, austria) is an ema-/fda-approved adalimumab biosimilar.The effect of sdz-adl on quality of life (qo l) and patient-reported outcomes (pros) was assessed as part of two phase iii studies, one in patients with moderate-to-severe chronic plaque psoriasis (ps o; adaccess) and the other in patients with rheumatoid arthritis (ra; admyra).Additionally, adaccess included patients with psoriatic arthritis (ps a).Methods adaccess included 465 patients with ps o, whereas admyra included 353 patients with ra.Both studies evaluated and confirmed equivalent efficacy, similar safety, and immunogenicity of sdz-adl with reference adalimumab (ref-adl).A third of patients underwent multiple (four) treatment switches between study treatments starting at week 17 (adaccess); all patients switched from ref-adl to sdz-adl at week 24 (admyra).Assessed pros included dermatology life quality index (dlqi) and euro qol five-dimension health status questionnaire (eq-5d-5l) in adaccess, functional assessment of chronic illness therapy-fatigue scale (facit-fatigue) score in admyra, and health assessment questionnaire-disability index (haq-di) in both studies.Results in both studies, baseline scores for all pro assessments were comparable between the two treatment groups.In adaccess, mean dlqi decreased from baseline in both groups, and the mean (standard deviation [sd]) percent reductions from baseline in dlqi were comparable between groups at week 17 (sdz-adl, - 64.5 [80.3]; ref-adl, - 70.6 [41.7]), which were sustained after the switch at week 51 ('continued sdz-adl,' - 79.7 [36.2]; 'continued ref-adl,' - 80.8 [44.6]; 'switched to sdz-adl,' - 70.7 [32.2]; 'switched to ref-adl,' - 69.3 [49.6]).In adaccess, the proportion of patients with an eq-5d-5l score of 1 (no problems) increased from baseline for all five dimensions in all treatment groups and was comparable between treatment groups at week 51.In adaccess, in patients with ps a at baseline, mean (sd) haq-di scores decreased from baseline in both treatment groups, and scores were comparable between groups at week 17 (sdz-adl, 0.5 [0.6]; ref-adl, 0.5 [0.6]) and after switching at week 51 ('continued sdz-adl,' 0.4 [0.5]; 'continued ref-adl,' 0.4 [0.6]; 'switched to sdz-adl,' 0.5 [0.8]; 'switched to ref-adl,' 0.7 [0.6]).In admyra, proportion of patients achieving haq-di in the normal range (≤ 0.5) was comparable between treatment groups at week 24 (sdz-adl, 37.8%; ref-adl, 36.3%) and after switching at week 48 ('sdz-adl,' 41.6%; 'ref-adl/switched to sdz-adl,' 40.0%).In admyra, mean facit-fatigue scores increased from baseline in both treatment groups.At week 24, mean (sd) percent change from baseline in the facit-fatigue scores was 75.4 (135.5) in sdz-adl and 73.0 (96.3) in ref-adl groups; the scores were sustained after switching at week 48.Conclusion treatment with sdz-adl and ref-adl resulted in comparable improvements in pros as well as qo l scores across the three diseases, ps o, ps a, and ra.Switching between sdz-adl and ref-adl had no negative impact on pros across the reported period.Clinical trials.Gov identifier nct02744755, nct02016105.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2021)
Publication types: Clinical Trial, Phase III;Journal Article;Randomized Controlled Trial